Hepatic Arterial Phase on Gadoxetic Acid-Enhanced Liver MR Imaging: A Randomized Comparison of 0.5 mL/s and 1 mL/s Injection Rates

다국어 초록 (Multilingual Abstract)

Objective: To compare gadoxetic acid injection rates of 0.5 mL/s and 1 mL/s for hepatic arterial-phase magnetic resonance (MR) imaging.
Materials and Methods: In this prospective study, 101 consecutive patients with suspected focal liver lesions were included and randomly divided into two groups. Each group underwent dynamic liver MR imaging using a 3.0-T scanner after an intravenous injection of gadoxetic acid at rates of either 0.5 mL/s (n = 50) or 1 mL/s (n = 51). Arterial phase images were analyzed after blinding the injection rates. The signal-to-noise ratios (SNRs) of the liver, aorta, portal vein, hepatic vein, spleen, and pancreas were measured. The contrast-to-noise ratios (CNRs) of the hepatocellular carcinomas (HCC) were calculated. Finally, two experienced radiologists were independently asked to identify, if any, HCCs in the liver on the images and score the image quality in terms of the presence of artifacts and the proper enhancement of the liver, aorta, portal vein, hepatic vein, hepatic artery, spleen, pancreas, and kidney.
Results: The SNRs were not significantly different between the groups (p = 0.233–0.965). The CNRs of the HCCs were not significantly different (p = 0.597). The sensitivity for HCC detection and the image quality scores were not significantly different between the two injection rates (p = 0.082–1.000).
Conclusion: Image quality and sensitivity for hepatic HCCs of arterial-phase gadoxetic acid-enhanced MR were not significantly improved by reducing the contrast injection rate to 0.5 mL/s compared with 1 mL/s.

참고문헌 (Reference)

1 Zech CJ, "Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA" 44 : 305-310, 2009

2 Trevisani F, "Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status" 34 : 570-575, 2001

3 Brugières P, "Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA)" 36 : 27-30, 1994

4 Korean Liver Cancer Study Group and National Cancer Center, Korea, "Practice guidelines for management of hepatocellular carcinoma 2009" 15 : 391-423, 2009

5 Reimer P, "Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence" 199 : 177-183, 1996

6 Hamm B, "Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging" 195 : 785-792, 1995

7 Schmid-Tannwald C, "Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate" 53 : 961-965, 2012

8 Bruix J, "Management of hepatocellular carcinoma: an update" 53 : 1020-1022, 2011

9 Vogl TJ, "Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA" 200 : 59-67, 1996

10 Halavaara J, "Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial" 30 : 345-354, 2006

11 Huppertz A, "Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings" 230 : 266-275, 2004

12 Raman SS, "Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial" 34 : 163-172, 2010

13 Jang HJ, "Imaging of focal liver lesions" 44 : 266-282, 2009

14 Bartolozzi C, "Focal liver lesions: MR imaging-pathologic correlation" 11 : 1374-1388, 2001

15 Huppertz A, "Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations" 234 : 468-478, 2005

16 Reimer P, "Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging" 7 : 275-280, 1997

17 Bluemke DA, "Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study" 237 : 89-98, 2005

18 Hammerstingl R, "Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions" 18 : 457-467, 2008

19 Brasch RC, "Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex" 142 : 625-630, 1984

20 Chung SH, "Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver" 31 : 365-372, 2010

21 Rohrer M, "Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths" 40 : 715-724, 2005

22 Ba-Ssalamah A, "Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions" 19 : 342-357, 2009

23 Weinmann HJ, "Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent" 142 : 619-624, 1984

24 Hendrick RE, "Basic physics of MR contrast agents and maximization of image contrast" 3 : 137-148, 1993